17 completed, 4 terminated, 2 withdrawn, 1 recruiting. 6 Phase 3, 6 Phase 4, 4 Phase 2, 3 Not applicable, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Terminated 2 |
| Phase 4 | 6 | Completed 6 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Not applicable | 3 | Withdrawn 2, Completed 1 |
| Phase 1 | 3 | Completed 3 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Gatifloxacin: new trials by email Literature Review of Gatifloxacin trials Research Report on Gatifloxacin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Pazufloxacin, Zymar - Conjunctivitis, Bacterial | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 46 | 2018-10-01 | 2021-08-24 |
| Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis anti-tuberculosis drug - Tuberculosis | Recruiting | Beijing Children's Hospital | 800 | 2018-07-01 | 2018-08-15 | |
| Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis PACK-CXL, Cefazolin in combination with either tobramycin or gentamicin, Cycloplegic agents (cyclopentolate 1% eye drops) - Keratitis; Infectious Disease (Manifestation) | Phase 3 | Completed | University Hospital, Geneva | 35 | 2016-03-01 | 2020-10-20 |
| Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) PRO-157, Vigamox, Zymar® - Bacterial Conjunctivitis | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 150 | 2015-03-01 | 2019-05-22 |
| Patients Response to Early Switch To Oral:Osteomyelitis Study oral antibiotics, intravenous antibiotics - Osteomyelitis | Early Phase 1 | Terminated | Julio Ramirez | 11 | 2014-03-06 | 2021-04-06 |
| A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution - Corneal Ulcers | Phase 2 | Terminated | Cornea Consultants Of Nashville | 2 | 2013-07-01 | 2015-08-13 |
| Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever Ceftriaxone, Gatifloxacin - Enteric Fever, Typhoid Fever | Phase 4 | Completed | Oxford University Clinical Research Unit, Vietnam | 300 | 2011-09-01 | 2016-10-04 |
| Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Besivance, Gatifloxacin - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 33 | 2011-05-01 | 2014-09-03 |
| Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation Gatifloxacin, Moxifloxacin, Besifloxacin - Healthy | Phase 1 | Completed | Bausch & Lomb Incorporated | 119 | 2009-03-01 | 2011-12-09 |
| A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3% - Anti-biotic Resistance | Phase 4 | Completed | Allergan | 66 | 2009-03-01 | 2011-12-19 |
| Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin - Cataract Extraction | Phase 1 | Completed | Bausch & Lomb Incorporated | 105 | 2009-02-01 | 2011-12-13 |
| Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation 0.3% gatifloxacin and 1.0% prednisolone acetate association, isolated 0.3% gatifloxacin and 1.0% prednisolone acetate - Ocular Infection and Inflammation | Phase 3 | Completed | Federal University of São Paulo | 101 | 2009-01-01 | 2018-03-21 |
| Topical Antibiotics and Intravitreous Injections gatifloxacin - Intravitreous, Injections | Phase 4 | Completed | Stanford University | 129 | 2008-07-01 | 2017-11-06 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 859 | 2008-02-01 | 2019-04-23 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 578 | 2007-08-01 | 2011-11-30 |
| A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis gatifloxacin, moxifloxacin 0.5% eye drops - Bacterial Conjunctivitis | Phase 4 | Completed | Allergan | 171 | 2007-06-01 | 2011-09-21 |
| Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application gatifloxacin, moxifloxacin - Conjunctical Flora | Not applicable | Withdrawn | Stanford University | 2007-04-01 | 2013-06-13 | |
| One Hour Preoperative Gatifloxacin Zymar - Ophthalmic Surgery | Phase 4 | Completed | Stanford University | 60 | 2007-01-01 | 2015-01-29 |
| Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK gatifloxacin and moxifloxacin - Corneal Epithelial Wound Healing | Completed | Donnenfeld, Eric, M.D. | 22 | 2007-01-01 | 2007-12-10 | |
| Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery gatifloxacin ophthalmic (ZYMAR) - Endophthalmitis | Not applicable | Withdrawn | Queen's University | 2006-06-01 | 2018-05-02 |
Showing 20 of 24. Sign in to see all of them.
Conjunctivitis, Bacterial (6) · Tuberculosis (2) · Communicable Diseases (1) · Corneal Ulcer (1) · Endophthalmitis (1) · Eye Infections (1) · Eye Infections, Bacterial (1) · Inflammation (1) · Keratitis (1) · Osteomyelitis (1) · Typhoid Fever (1)
Allergan (5) · Bausch & Lomb Incorporated (3) · Stanford University (3) · Laboratorios Sophia S.A de C.V. (2) · Beijing Children's Hospital (1) · Cornea Consultants Of Nashville (1) · Donnenfeld, Eric, M.D. (1) · Federal University of São Paulo (1) · Innovative Medical (1) · Julio Ramirez (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oxford University Clinical Research Unit, Vietnam (1) · Queen's University (1) · University Hospital, Geneva (1) · Walter Reed Army Medical Center (1)
United States (15) · Canada (3) · Brazil (2) · India (2) · Mexico (2) · China (1) · Nepal (1) · Switzerland (1)
Christopher Ta, MD (3) · A-Dong Shen, Master (1) · Buddha Basnyat, MD (1) · David Seligson, MD (1) · Eric Donnefeld (1) · Eric Donnenfeld, MD (1) · Farhad Hafezi, MD, PhD (1) · Ira A. Shivitz, M.D. (1) · Johnson Varughese (1) · Julio Ramirez, MD (1) · Leopoldo Baiza, MD (1) · Sherif El-Defrawy, MD PhD FRCSC (1)
PMID 15276398, PMID 15840453, PMID 16776446, PMID 18070980, PMID 18787216, PMID 19564361, PMID 19588358, PMID 19923475, PMID 22530208, PMID 25244402, PMID 26809813, PMID 29584861, PMID 32557558, PMID 34996516, PMID 4902833, PMID 8948280